Schmidt Thomas, Fuchs Hans F, Thomas Michael N, Müller Dolores T, Lukomski Leandra, Scholz Matthias, Bruns Christiane J
Klinik und Poliklinik für Allgemein‑, Viszeral‑, Tumor- und Transplantationschirurgie, Uniklinik Köln, Kerpenerstr. 62, 50937, Köln, Deutschland.
Chirurgie (Heidelb). 2024 Apr;95(4):261-267. doi: 10.1007/s00104-024-02056-3. Epub 2024 Feb 27.
The surgical options and particularly perioperative treatment, have significantly advanced in the case of gastroesophageal cancer. This progress enables a 5-year survival rate of nearly 50% to be achieved through curative multimodal treatment concepts for locally advanced cancer. Therefore, in tumor boards and surgical case discussions the question increasingly arises regarding the type of treatment that provides optimal oncological and functional outcomes for individual patients with pre-existing diseases. It is therefore essential to carefully assess whether organ-preserving treatment might also be considered in the future or in what way minimally invasive or robotic surgery can offer advantages. Simultaneously, the boundaries of surgical and oncological treatment are currently being shifted in order to enable curative forms of treatment for patients with pre-existing conditions or those with oligometastatic diseases. With the integration of artificial intelligence into decision-making processes, new possibilities for information processing are increasingly becoming available to incorporate even more data into making decisions in the future.
对于食管癌，手术选择尤其是围手术期治疗已经取得了显著进展。这一进展使得通过针对局部晚期癌症的多模式治愈性治疗理念，能够实现近50%的5年生存率。因此，在肿瘤多学科讨论组和手术病例讨论中，对于为患有基础疾病的个体患者提供最佳肿瘤学和功能结果的治疗类型的问题日益凸显。因此，仔细评估未来是否也可考虑保留器官的治疗，或者微创或机器人手术能以何种方式带来优势至关重要。同时，目前手术和肿瘤治疗的界限正在发生变化，以便为患有基础疾病或寡转移疾病的患者提供治愈性治疗形式。随着人工智能融入决策过程，未来越来越有可能获得新的信息处理方式，从而在决策中纳入更多数据。
